Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Accumulated Expenses (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Accumulated Expenses for 6 consecutive years, with $4.6 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 0.53% to $4.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.6 million through Dec 2025, up 0.53% year-over-year, with the annual reading at $4.6 million for FY2025, 0.53% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $4.6 million at Janux Therapeutics, down from $22.2 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $22.2 million in Q3 2025, with the low at $784000.0 in Q3 2021.
  • Average Accumulated Expenses over 5 years is $5.8 million, with a median of $4.6 million recorded in 2025.
  • The sharpest move saw Accumulated Expenses soared 644.76% in 2021, then plummeted 60.42% in 2025.
  • Over 5 years, Accumulated Expenses stood at $2.1 million in 2021, then soared by 121.41% to $4.7 million in 2022, then surged by 56.64% to $7.4 million in 2023, then plummeted by 38.19% to $4.6 million in 2024, then rose by 0.53% to $4.6 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $4.6 million, $22.2 million, and $2.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.